Cargando…
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Researchers have been looking for insulin-stimulating factors for more than 100 years, and in the 1960ties it was definitively proven that the gastrointestinal tract releases important insulinotropic factors upon oral glucose intake, so-called incretin hormones. The first significant factor identifi...
Autor principal: | Holst, Jens Juul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497767/ https://www.ncbi.nlm.nih.gov/pubmed/31080438 http://dx.doi.org/10.3389/fendo.2019.00260 |
Ejemplares similares
-
The Origin and Understanding of the Incretin Concept
por: Rehfeld, Jens F.
Publicado: (2018) -
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020) -
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
por: Boer, Geke Aline, et al.
Publicado: (2020) -
Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture
por: Holst, Jens Juul
Publicado: (2021) -
Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)